Sesen Bio, Inc. (SESN): Price and Financial Metrics


Sesen Bio, Inc. (SESN): $0.51

0.06 (+14.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SESN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SESN POWR Grades


  • Growth is the dimension where SESN ranks best; there it ranks ahead of 88.18% of US stocks.
  • SESN's strongest trending metric is Value; it's been moving up over the last 179 days.
  • SESN's current lowest rank is in the Momentum metric (where it is better than 4.64% of US stocks).

SESN Stock Summary

  • The ratio of debt to operating expenses for Sesen Bio Inc is higher than it is for about merely 0.5% of US stocks.
  • The volatility of Sesen Bio Inc's share price is greater than that of 99.65% US stocks with at least 200 days of trading history.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SESN comes in at -130.82% -- higher than that of only 2.83% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Sesen Bio Inc, a group of peers worth examining would be BB, GORO, CEMI, ACIW, and DSGX.
  • SESN's SEC filings can be seen here. And to visit Sesen Bio Inc's official web site, go to www.sesenbio.com.

SESN Valuation Summary

  • In comparison to the median Healthcare stock, SESN's EV/EBIT ratio is 101.02% lower, now standing at -0.3.
  • SESN's price/sales ratio has moved down 107.5 over the prior 92 months.
  • Over the past 92 months, SESN's price/sales ratio has gone down 107.5.

Below are key valuation metrics over time for SESN.

Stock Date P/S P/B P/E EV/EBIT
SESN 2021-08-31 12.0 3.8 -1.6 -0.3
SESN 2021-08-30 11.6 3.7 -1.5 -0.3
SESN 2021-08-27 12.3 3.9 -1.6 -0.3
SESN 2021-08-26 12.6 4.0 -1.7 -0.4
SESN 2021-08-25 13.5 4.2 -1.8 -0.5
SESN 2021-08-24 13.2 4.2 -1.7 -0.5

SESN Growth Metrics

    Its 4 year price growth rate is now at -31.46%.
  • The 3 year revenue growth rate now stands at -100%.
  • Its 5 year net income to common stockholders growth rate is now at -93.07%.
Over the past 70 months, SESN's revenue has gone up $25,569,000.

The table below shows SESN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 26.544 -68.878 -0.336
2021-09-30 6.544 -64.787 -24.341
2021-06-30 17.78 -54.127 -118.571
2021-03-31 15.546 -40.474 -119.473
2020-12-31 11.236 -30.837 -22.544
2020-09-30 11.236 -36.133 -48.098

SESN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SESN has a Quality Grade of C, ranking ahead of 52.29% of graded US stocks.
  • SESN's asset turnover comes in at 0.094 -- ranking 266th of 682 Pharmaceutical Products stocks.
  • SVRA, AUPH, and ONVO are the stocks whose asset turnover ratios are most correlated with SESN.

The table below shows SESN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.094 1 511.326
2021-03-31 0.120 1 31.068
2020-12-31 0.103 1 4.319
2020-09-30 0.105 1 14.394
2020-06-30 0.000 NA 7.880
2020-03-31 0.000 NA 13.068

SESN Price Target

For more insight on analysts targets of SESN, see our SESN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $2.25 Average Broker Recommendation 1.67 (Moderate Buy)

SESN Stock Price Chart Interactive Chart >

Price chart for SESN

SESN Price/Volume Stats

Current price $0.51 52-week high $6.04
Prev. close $0.45 52-week low $0.37
Day low $0.46 Volume 4,808,400
Day high $0.54 Avg. volume 3,149,952
50-day MA $0.55 Dividend yield N/A
200-day MA $0.94 Market Cap 102.29M

Sesen Bio, Inc. (SESN) Company Bio


Sesen Bio (formerly Eleven Biotherapeutics, Inc.), a biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company was founded in 2008 and is based in Cambridge, Massachusetts.


SESN Latest News Stream


Event/Time News Detail
Loading, please wait...

SESN Latest Social Stream


Loading social stream, please wait...

View Full SESN Social Stream

Latest SESN News From Around the Web

Below are the latest news stories about Sesen Bio Inc that investors may wish to consider to help them evaluate SESN as an investment opportunity.

Sesen Bio: Q4 Earnings Insights

Sesen Bio (NASDAQ: SESN ) reported its Q4 earnings results on Monday, February 28, 2022 at 08:00 AM. Here''s what investors need to know about the announcement. Earnings Sesen Bio beat estimated earnings by 157.14%, reporting … Full story available on Benzinga.com

Benzinga | February 28, 2022

Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2021. During the fourth quarter, the Company worked with the US Food and Drug Administration (FDA) to identify an anticipated regulatory path toward potential resubmission of a Biologics License Application (BLA) for the Company

Business Wire | February 28, 2022

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 17, 2022

Sesen Bio Further Enhances Team with Key Hires

CAMBRIDGE, Mass., January 10, 2022--Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022.

Yahoo | January 10, 2022

Lifshitz Law Firm, P.C. Announces Investigations of Generac Holdings Inc. (NYSE: GNRC), Katapult Holdings, Inc. (NASDAQGM: KPLT), PayPal Holdings, Inc. (NASDAQGS: PYPL), and SeSen Bio, Inc. (NASDAQGM: SESN)

NEW YORK, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Generac Holdings Inc. (NYSE: GNRC)

GlobeNewswire | December 23, 2021

Read More 'SESN' Stories Here

SESN Price Returns

1-mo 5.28%
3-mo -23.94%
6-mo -52.34%
1-year -81.91%
3-year -70.86%
5-year -65.54%
YTD -37.42%
2021 -39.63%
2020 29.81%
2019 -26.76%
2018 75.09%
2017 -57.54%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5226 seconds.